MCM
ABBV icon

Murphy Capital Management’s AbbVie ABBV Stock Holding History

Murphy Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$895K Buy
5,847
+86
+1% +$13.1K 0.12% 114
2022
Q1 		$933K Sell
5,761
-6
-0.1% -$872 0.11% 115
2021
Q4 		$780K Sell
5,767
-373
-6% -$44.1K 0.08% 130
2021
Q3 		$662K Sell
6,140
-51
-0.8% -$5.83K 0.08% 138
2021
Q2 		$697K Sell
6,191
-562
-8% -$63.3K 0.08% 136
2021
Q1 		$730K Buy
6,753
+451
+7% +$48.2K 0.09% 132
2020
Q4 		$675K Sell
6,302
-601
-9% -$57.8K 0.09% 130
2020
Q3 		$604K Buy
6,903
+67
+1% +$6.31K 0.09% 125
2020
Q2 		$671K Buy
6,836
+1,681
+33% +$148K 0.11% 124
2020
Q1 		$392K Sell
5,155
-38
-0.7% -$3.24K 0.07% 143
2019
Q4 		$459K Sell
5,193
-1,162
-18% -$96.5K 0.07% 152
2019
Q3 		$481K Sell
6,355
-451
-7% -$30.9K 0.07% 154
2019
Q2 		$494K Sell
6,806
-285
-4% -$22.4K 0.07% 158
2019
Q1 		$571K Sell
7,091
-750
-10% -$61.4K 0.09% 157
2018
Q4 		$722K Sell
7,841
-225
-3% -$19.8K 0.12% 132
2018
Q3 		$762K Sell
8,066
-35
-0.4% -$3.32K 0.11% 144
2018
Q2 		$750K Sell
8,101
-1,475
-15% -$144K 0.11% 145
2018
Q1 		$906K Sell
9,576
-325
-3% -$35.7K 0.13% 139
2017
Q4 		$957K Hold
9,901
– – 0.13% 136
2017
Q3 		$879K Sell
9,901
-100
-1% -$7.61K 0.13% 139
2017
Q2 		$725K Hold
10,001
– – 0.11% 151
2017
Q1 		$651K Hold
10,001
– – 0.1% 160
2016
Q4 		$626K Sell
10,001
-250
-2% -$15.3K 0.1% 161
2016
Q3 		$646K Buy
10,251
+1,000
+11% +$64.7K 0.1% 167
2016
Q2 		$572K Buy
9,251
+159
+2% +$9.69K 0.09% 185
2016
Q1 		$519K Sell
9,092
-2,259
-20% -$126K 0.08% 190
2015
Q4 		$672K Buy
11,351
+1,588
+16% +$91.5K 0.1% 171
2015
Q3 		$531K Sell
9,763
-1,138
-10% -$74.1K 0.09% 185
2015
Q2 		$732K Buy
10,901
+2,450
+29% +$160K 0.11% 172
2015
Q1 		$494K Buy
8,451
+2,500
+42% +$151K 0.07% 203
2014
Q4 		$389K Buy
+5,951
New +$375K 0.06% 235

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Murphy Capital Management's ABBV Position: Q2 2022 in Review

Murphy Capital Management increased its AbbVie (ABBV) stake by 1.5% in Q2 2022, buying an estimated $13.1K and bringing the position to 5,847 shares worth $895K. The position accounts for 0.12% of the portfolio, ranked #114.

Murphy Capital Management first reported a position in ABBV in Q4 2014 and has held it in 31 quarters since. The position peaked at $957K in Q4 2017. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Murphy Capital Management held 5,847 shares of AbbVie worth $895K as of Q2 2022.
  • Murphy Capital Management bought 86 AbbVie shares in Q2 2022, an estimated $13.1K.
  • AbbVie made up 0.12% of Murphy Capital Management's portfolio in Q2 2022, its #114 holding.
  • Murphy Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 31 quarters since.
  • Murphy Capital Management's AbbVie position peaked at $957K in Q4 2017.
  • 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Murphy Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.